InMode Ltd. (INMD) shares surged nearly 14% during Monday morning trading, reaching an intraday high of $15.88 following reports of advanced acquisition talks.
The move comes after the Israeli newspaper Calcalist reported that a foreign investment fund is in discussions to purchase the medical device company for approximately $1.1 billion.
The potential deal, which would take the company private and delist it from the Nasdaq, represents a premium of about 24% to Friday's closing price.
According to market analysis, Bank of America has been formally engaged to manage the sale process and solicit the highest possible bid for the aesthetic medical technology provider.
While the news sparked an immediate rally, InMode has faced a difficult period, with its stock price down nearly 11% over the past year.
Investors are weighing the potential premium exit against recent operational struggles and broader industry headwinds.
Key Takeaways
- INMD stock jumped nearly 14% Monday on reports of a $1.1 billion acquisition offer.
- The proposed deal represents a 23.5% to 25% premium over the previous Friday’s closing price.
- Bank of America is reportedly managing the sale process for the aesthetic device maker.
- The acquisition would take InMode private, following a year of declining revenue and profits.
- Recent sector pressure includes a 2025 FDA warning regarding radiofrequency microneedling devices.
| Current Price | $15.47 |
| Daily Change | +10.86% 🟢 |
| Day High | $15.90 |
| Day Low | $15.20 |
| Year High | $19.78 |
| Year Low | $13.14 |
What Triggered INMD's 13% Stock Surge Today?
The primary catalyst for today’s rally is a report from Calcalist indicating that InMode is in the late stages of negotiations with an unnamed foreign investment fund.
According to Investing.com, the deal aims to value the company at approximately $1.1 billion.
This news immediately boosted investor confidence, sending shares toward a high of $15.88.
The report suggests that the company is looking to delist from the Nasdaq and transition to private ownership, a move that would end its tenure as a public entity.
Behind the Deal: A Premium Exit Amidst InMode's Recent Challenges?
The reported $1.1 billion valuation offers shareholders a significant exit premium.
The deal is structured at roughly 24% above the stock's closing price from the previous Friday, providing a buffer for investors who have seen the stock struggle.
Bank of America’s involvement as the sale advisor signals a formal attempt to maximize value, as many investors wonder what happens to shares in an acquisition.
Analysts at BTIG noted that such an acquisition “wouldn’t completely surprise” given the persistent stock pressure InMode has faced over the last several years.
The company’s revenue has declined roughly 25% from its peak in 2023.
How Does the $1.1 Billion Valuation Compare to Current Metrics?
Prior to the report, InMode's market capitalization sat at approximately $963 million.
The proposed $1.1 billion price tag places the deal at specific valuation multiples based on 2026 consensus estimates.
These include 1.5x EV/Sales, 6x EV/EBITDA, and an 8.5x P/E ratio.
For comparison, InMode currently trades at a price-to-earnings (P/E) ratio of 6.29 and an EV/EBITDA of 4.03.
Data from InvestingPro Fair Value estimates previously suggested that the company was undervalued, making it an attractive target.
| 🟢 Bull Case | 🔴 Bear Case |
|---|---|
| • Reported $1.1B acquisition offer at ~24% premium | • Significant 28% YoY revenue decline in Q3 2025 |
| • Q3 2025 earnings beat ($0.38 vs $0.36 forecast) | • 2025 FDA warning on RF microneedling safety |
| • InvestingPro Fair Value suggests undervaluation | • High interest rates impacting device financing |
| • Potential for premium exit from stock pressure | • Cautious consumer sentiment in aesthetics market |
InMode's Financial Performance & Industry Headwinds Leading Up to the Offer
InMode has dealt with several operational setbacks recently. In November 2025, the company reported third-quarter revenue of $93.16 million.
This was a 28% year-over-year decline from the $130.2 million reported in the same period in 2024.
Despite beating lowered analyst expectations for that quarter, the downward trend in sales has remained a concern.
The company also issued preliminary guidance for the full year 2025, projecting revenue between $370.2 million and $370.4 million.
Furthermore, the medical aesthetics sector was rattled in October 2025 when the FDA issued a warning regarding health risks associated with radiofrequency microneedling devices.
How INMD's Surge Outperformed the Medical Devices Sector
InMode's double-digit gain today stands in stark contrast to the broader medical devices industry.
While INMD rose nearly 11% in midday trading, the industry average change for the day was a modest 0.21%.
The stock's performance significantly outpaced large-cap peers and sector competitors alike, which is common during speculative moves in small cap stocks.
Financial data shows that peers like Medtronic (MDT) and Intuitive Surgical (ISRG) saw gains of less than 1.2%.
InMode's massive outperformance highlights that today's move is tied strictly to the acquisition report rather than a sector-wide recovery.
| Company | Symbol | Daily Change |
|---|---|---|
| TransMedics Group | TMDX | +1.64% |
| Alphatec Holdings | ATEC | +1.54% |
| Intuitive Surgical | ISRG | +1.15% |
| Medtronic plc | MDT | +0.60% |
| Industry Average | – | +0.21% |
| InMode Ltd. | INMD | +10.86% 🟢 |
| Pulse Biosciences | PLSE | -5.10% |
What Should Investors Watch Next for InMode?
The investment community is now focused on the confirmation of these acquisition talks.
While Calcalist reported the negotiations are advanced, no official agreement has been signed yet.
Investors should also look toward February 10, 2026, when InMode is scheduled to report its final fourth-quarter and full-year 2025 financial results.
Management is expected to provide further clarity on its 2026 revenue guidance, currently projected between $365 million and $375 million.
The Bottom Line
The reported acquisition offer provides a potential lifeline for InMode shareholders following a period of declining profits.
While the $1.1 billion valuation offers a healthy premium, the deal's completion remains subject to formal confirmation.
Despite the bullish reaction, InMode still faces a challenging macroeconomic environment and cautious consumer sentiment in the aesthetic market.
